<DOC>
	<DOCNO>NCT00550849</DOCNO>
	<brief_summary>This study assess safety tolerability RTA 402 patient liver disease .</brief_summary>
	<brief_title>Study Assess Safety , Tolerability , Pharmacodynamics RTA 402 Patients With Hepatic Dysfunction</brief_title>
	<detailed_description>RTA 402 synthetic triterpenoid design suppress oxidative stress inflammatory process play significant role wide variety disease . It potent suppressor inflammation oxidative stress . Oxidative stress play role pathogenesis hepatitis , RTA 402 demonstrate activity preclinical model hepatitis , addition model inflammation . This 28-day , multiple-dose , dose-escalation study . It anticipate total 3 group 8 patient enrol , 6 patient group randomize receive RTA 402 , 2 patient per group randomize placebo ( 3:1 ) . Patients receive treatment daily 14 day start dose 5mg , 25mg , 50mg . Patients return follow visit Days 16 21 , complete end study procedure Day 28 .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Chronic liver disease . An estimated creatinine clearance â‰¥ 60 mL/min . Serum alanine transaminase ( ALT ) aspartate transaminase ( AST ) elevation must upper limit normal 5 time upper limit normal patient underlie liver disease ; ChildPugh score 5 9 ( mild moderate impairment ) . Patient must agree practice effective contraception entire study period . Patient willing avoid strenuous physical activity 24 hour prior study start , throughout study , 2 week administration dose study drug Patient willing avoid alcohol consumption 24 hour prior , 48 hour administration study drug ; avoid excessive alcohol consumption duration followup period . Patient must able willing sign inform consent form . Patient clinically significant illness recent hospitalization ( within 60 day ) could compromise participation study judgment investigator , include : uncontrolled diabetes ; active uncontrolled infection ; Confirmed diagnosis HIV infection ; uncontrolled hypertension , symptomatic congestive heart failure , unstable angina pectoris , myocardial infarction within past 6 month , uncontrolled cardiac arrhythmia . Patient auto immune disease , major chronic inflammatory disease syndrome require significant treatment within past year . Patients pregnant breast feed Patient receive receive investigational drug within 30 day prior ( currently use investigational device ) Patients prior ( within 4 week ) concurrent treatment oral steroid , proteinbased therapy ( i.e . TNFa ) Patients positive urine screen drug abuse except receive prescribed medication know indication Patients Grade 2 hepatic encephalopathy . Patients donate blood experienced significant blood loss ( &gt; 450 mL ) within 8 week screen Patients history bleed varix within 12 week screen . Patients psychiatric illness condition would limit compliance study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>